SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001104659-24-033080
Filing Date
2024-03-11
Accepted
2024-03-11 17:16:06
Documents
4
Period of Report
2024-03-21

Document Format Files

Seq Description Document Type Size
1 DEF 14A tm2333863-2_def14a.htm DEF 14A 233381
2 GRAPHIC lg_nrx-4c.jpg GRAPHIC 19295
3 GRAPHIC px_24nrxspecialmeet01-bw.jpg GRAPHIC 332422
4 GRAPHIC px_24nrxspecialmeet02-bw.jpg GRAPHIC 249127
  Complete submission text file 0001104659-24-033080.txt   999693
Mailing Address 1201 ORANGE STREET SUITE 600 WILMINGTON DE 19801
Business Address 1201 ORANGE STREET SUITE 600 WILMINGTON DE 19801 484-254-6134
NRX Pharmaceuticals, Inc. (Filer) CIK: 0001719406 (see all company filings)

IRS No.: 822844431 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-38302 | Film No.: 24739124
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)